Autoimmunity in Retinitis Pigmentosa

The recruitment status of this study is unknown because the information has not been verified recently.

Verified February 2007 by Semmelweis University.
Recruitment status was Active, not recruiting

Sponsor:

Information provided by:

Semmelweis University

ClinicalTrials.gov Identifier:

NCT00433277

First received: February 6, 2007

Last updated: February 8, 2007

Last verified: February 2007

History of Changes

Purpose

Using local immune suppression, the trial seeks evidence for the hypothesis that autoimmunity plays a role in the pathomechanism of retinitis pigmentosa.

Condition	Intervention
Retinitis Pigmentosa	Drug: twice-daily dosage with 0.5% cyclosporine-A eyedrops

Study Type:	Interventional
Study Design:	Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: Open Label

Resource links provided by NLM:

Genetics Home Reference related topics: Lenz microphthalmia syndrome oculofaciocardiodental syndrome Peters plus syndrome retinitis pigmentosa X-linked juvenile retinoschisis

Drug Information available for: Cyclosporine

U.S. FDA Resources

Further study details as provided by Semmelweis University:

Eligibility

Genders Eligible for Study:

Both

Criteria

Inclusion Criteria:

Clinical diagnosis of retinitis pigmentosa

Exclusion Criteria:

Cataract
Extremely low ERG wave amplitude (less than 8% of normal)

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00433277

Locations

Hungary
Semmelweis University, Dept. of Ophthalmology
Budapest, Hungary, H-1085

Sponsors and Collaborators

Semmelweis University

Investigators

Study Director:

Zoltán Z. Nagy, M.D.

Semmelweis University, Dept. of Ophthalmology

More Information

No publications provided

ClinicalTrials.gov Identifier:	NCT00433277 History of Changes
Other Study ID Numbers:	KMolnar
Study First Received:	February 6, 2007
Last Updated:	February 8, 2007
Health Authority:	Hungary: National Institute of Pharmacy

Additional relevant MeSH terms:

Retinitis
Retinitis Pigmentosa
Retinal Diseases
Eye Diseases
Eye Diseases, Hereditary
Retinal Dystrophies
Retinal Degeneration
Genetic Diseases, Inborn
Cyclosporins
Cyclosporine
Enzyme Inhibitors

Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antifungal Agents
Anti-Infective Agents
Therapeutic Uses
Dermatologic Agents
Antirheumatic Agents

ClinicalTrials.gov processed this record on May 21, 2013

To Top